WCN26-6446 Vanishing Bile Duct Syndrome related to Avacopan Therapy in a Patient with ANCA-Associated Vasculitis

Read full text Summarise with VIRAT
Authors: Masatora Yamasaki, Makoto Fukuda, Kohei Hashimoto, Eriko Nonaka, Maki Yoshihara, Motoaki Miyazono
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ANCA-associated vasculitis is a disease that causes rapidly progressive glomerulonephritis. Avacopan, a C5a receptor inhibitor, is used as a new treatment for ANCA-associated vasculitis. However, in recent years, reports of drug-induced liver injury (DILI), including vanishing bile duct syndrome(VBDS), have been sporadically observed.

Fields of Study & Subjects

Vasculitis and related conditions Drug-Induced Hepatotoxicity and Protection Pharmacovigilance and Adverse Drug Reactions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104000–104000
Publication date
25 March 2026
Language
EN